Latest Breaking News On - Late breaking clinical trial - Page 1 : comparemela.com

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesStuart kupferDiane weiserMary ellen jayGregory lewisEuropean society of cardiologyNational medical products administrationCytokinetics incorporatedUs food drug administrationSchool of cardiovascularMetabolic healthJournal of the american college cardiologyExchange commissionInternational congressCardiopulmonary exercise testing laboratory

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesDiane weiserMartin maronFadyi malikCytokinetics incorporated nasdaqUs food drug administrationCorporate affairsHypertrophic cardiomyopathy centerResearch developmentGlobenewswire incEuropean society of cardiologyCompany to host investor eventNational medical products administrationJournal of the american college cardiologySymphony healthPestana palace lisboa hotel

Cytokinetics (CYTK) Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial

Cytokinetics (CYTK) Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomMary ellen jayGregory lewisStuart kupferUniversity of glasgowScotland inherited cardiac conditions serviceMetabolic healthCytokinetics incorporated nasdaqEuropean society of cardiologyCardiopulmonary exercise testing laboratoryHarvard medical schoolSchool of cardiovascularInternational congressQuantitative understandingObstruction impactHeart failure

Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress - Cytokinetics (NASDAQ:CYTK)

SOUTH SAN FRANCISCO, Calif., April 29, 2024 (GLOBE NEWSWIRE) Cytokinetics, Incorporated (NASDAQ:CYTK) today announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European

United kingdomMartin maronPerry elliottGregory lewisMary ellen jayDiane weiserUniversity of glasgowEuropean society of cardiologyHarvard medical schoolInstitute for cardiovascular scienceCorporate affairsPestana palace lisboa hotelCytokinetics incorporatedExchange commissionScotland inherited cardiac conditions serviceUniversity college london

Ablative Solutions TARGET BP I Pivotal Trial Results Demonstrate Significant Reduction in 24-Hour Ambulatory Systolic Blood Pressure Compared to Sham, Using Alcohol-Mediated Renal Denervation

/PRNewswire/ Ablative Solutions, Inc., announced that primary trial results from the TARGET BP I Pivotal Trial, evaluating alcohol-mediated renal.

United statesKate rumrillDavid kandzariAblative solutionsAmerican college of cardiologyScientific congressPiedmont heart institutePrnewswire ablative solutions incAblative solutions incLate breaking clinical trialPrimary endpointUncontrolled hypertensionTreatment armPivotal trialPeregrine systemAmerican college